Orphan Drug Tax Credit Act of 2003

H.R. 2931, the Orphan Drug Tax Credit Act of 2003, aims to accelerate financial incentives for pharmaceutical companies developing treatments for rare diseases. Under this proposal, companies could begin claiming tax credits for clinical testing costs as soon as they apply for "orphan drug" status, rather than waiting for the official designation to be granted. By providing earlier access to these credits, the bill seeks to reduce the financial burden on researchers and potentially speed up the development of life-saving medications for patients with rare medical conditions.